Four Genes Drive Lung Scarring via Cellular Aging in New IPF Discovery
Researchers identify four endothelial senescence genes that predict IPF with 93.6% accuracy, and find valproic acid cuts lung collagen by 60% in mice.
Resumen
A new study pinpoints four genes tied to endothelial cell senescence (ECS) that play opposing roles in idiopathic pulmonary fibrosis (IPF). By analyzing transcriptomic data from 145 IPF patients and 84 controls, researchers identified MYCT1 and PLEKHA1 as protective anti-senescence factors that are suppressed in IPF, while PCDH12 and PLXND1 drive fibrosis and are elevated. A diagnostic model using these four genes achieved 93.6% accuracy. In cell and mouse models, silencing the pro-fibrotic genes reduced scarring markers by ~40%, and the drug valproic acid (VPA) cut collagen deposition by ~60%, suggesting a potential therapeutic path for this currently incurable lung disease.
Resumen detallado
Idiopathic pulmonary fibrosis (IPF) is a devastating and progressive lung disease with few effective treatments. Cellular senescence in endothelial cells lining the lung vasculature has emerged as a key contributor to disease progression, but the specific molecular mediators have remained poorly characterized—until now.
Researchers from Henan Provincial People's Hospital integrated two publicly available GEO transcriptome datasets comprising 145 IPF patients and 84 healthy controls. Using three machine learning approaches—LASSO regression, SVM-RFE, and the Boruta algorithm—they identified four endothelial cell senescence-related genes (ECSRGs): MYCT1, PLEKHA1, PCDH12, and PLXND1. MYCT1 and PLEKHA1 were significantly downregulated (~26% and ~75%, respectively), while PCDH12 and PLXND1 were upregulated 2.4- and 1.9-fold in IPF patients versus controls (all p < 0.0001).
A four-gene nomogram built on these markers delivered impressive diagnostic accuracy of 93.6%, suggesting strong translational potential as a non-invasive biomarker panel. Functional validation in TGF-β1-stimulated human umbilical vein endothelial cells (HUVECs) confirmed the mechanistic roles: silencing MYCT1 or PLEKHA1 increased senescent cell burden by ~1.4-fold, while silencing PCDH12 or PLXND1 reduced fibrosis markers α-SMA and COL1A1 by approximately 40%.
In a bleomycin-induced mouse model of pulmonary fibrosis, treatment with valproic acid (VPA)—an HDAC inhibitor already approved for other indications—reduced collagen deposition by ~60% and normalized expression of all four genes, pointing to a viable repurposing strategy.
Caveats include reliance on publicly available datasets, in vitro models that may not fully replicate human IPF, and the need for clinical validation of VPA efficacy and safety in IPF patients.
Hallazgos clave
- Four ECS-related genes (MYCT1, PLEKHA1, PCDH12, PLXND1) identified in IPF via multi-algorithm machine learning.
- MYCT1 and PLEKHA1 are anti-senescence factors downregulated in IPF; PCDH12 and PLXND1 are pro-fibrotic and upregulated.
- A four-gene diagnostic nomogram achieved 93.6% accuracy distinguishing IPF from healthy controls.
- Silencing PCDH12 or PLXND1 reduced fibrosis markers α-SMA and COL1A1 by ~40% in cell models.
- Valproic acid reduced collagen deposition by ~60% in bleomycin-treated mice and normalized gene expression.
Metodología
The study integrated two GEO transcriptome datasets (145 IPF patients, 84 controls) and applied LASSO, SVM-RFE, and Boruta machine learning algorithms to identify key genes. Functional validation used TGF-β1-induced HUVECs with gene silencing and a bleomycin-induced mouse fibrosis model treated with valproic acid.
Limitaciones del estudio
Findings are based on retrospective transcriptomic datasets and require prospective clinical validation. In vitro HUVEC models and bleomycin mouse models may not fully recapitulate human IPF pathophysiology. VPA's tolerability and efficacy in IPF patients remain untested in human trials.
¿Te ha gustado este resumen?
Recibe la última investigación sobre longevidad en tu bandeja de entrada cada semana.
Introduce tu correo electrónico para suscribirte: